<code id='DBE70A323A'></code><style id='DBE70A323A'></style>
    • <acronym id='DBE70A323A'></acronym>
      <center id='DBE70A323A'><center id='DBE70A323A'><tfoot id='DBE70A323A'></tfoot></center><abbr id='DBE70A323A'><dir id='DBE70A323A'><tfoot id='DBE70A323A'></tfoot><noframes id='DBE70A323A'>

    • <optgroup id='DBE70A323A'><strike id='DBE70A323A'><sup id='DBE70A323A'></sup></strike><code id='DBE70A323A'></code></optgroup>
        1. <b id='DBE70A323A'><label id='DBE70A323A'><select id='DBE70A323A'><dt id='DBE70A323A'><span id='DBE70A323A'></span></dt></select></label></b><u id='DBE70A323A'></u>
          <i id='DBE70A323A'><strike id='DBE70A323A'><tt id='DBE70A323A'><pre id='DBE70A323A'></pre></tt></strike></i>

          focus

          focus

          author:leisure time    Page View:458
          Adobe

          Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

          In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

          advertisement

          The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio
          The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

          RubyWallauforSTATWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne

          read more
          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more

          STAT readers on older presidents, polypills, Medicare, and more

          MollyFergusonforSTATSTATnowpublishesselectedLetterstotheEditorreceivedinresponsetoFirstOpinionessays